Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bard enrols first patient in Lutonix BTK study

Bard enrols first patient in Lutonix BTK study

6th June 2013

Bard has commenced a new study that will assess the Lutonix 014 Drug Coated PTA Dilatation Catheter in the treatment of below-the-knee (BTK) peripheral arterial disease

The first patient has been enrolled for the study at the Cardiac and Vascular Institute in Gainesville, which compares the safety and effectiveness of Lutonix drug-coated balloon technology to a standard angioplasty balloon when treating of critical limb ischaemia.

Several hundred patients will be involved in the trial across 55 sites worldwide, with the aim of potentially expanding treatment options for peripheral arterial disease.

The Lutonix 014 catheter is already commercially available in Europe but remains limited to investigational use in the US.

Dr Arthur Lee from the Cardiac and Vascular Institute said: "This patient population faces significant challenges and poor clinical outcomes. Drug-coated balloons potentially offer a new hope for more durable and long-term clinical outcomes for patients facing CLI."

During the first quarter of 2013, Bard generated a net sales total of $740.3 million (476.89 million pounds), up by one percent year over year.ADNFCR-8000103-ID-801595868-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.